[{"id":"ab21b4e4-b3ac-475c-9005-48c011e2a7c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316155","created_at":"2022-04-07T12:57:01.192Z","updated_at":"2025-02-25T15:27:19.690Z","phase":"Phase 1/2","brief_title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","source_id_and_acronym":"NCT05316155","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 09/19/2029","study_completion_date":" 09/19/2029","last_update_posted":"2025-02-10"},{"id":"0b4bc025-bfab-4d27-a83b-163254f008e0","acronym":"CR109248","url":"https://clinicaltrials.gov/study/NCT05567185","created_at":"2022-10-05T13:56:18.093Z","updated_at":"2024-07-02T16:35:02.053Z","phase":"Phase 1","brief_title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","source_id_and_acronym":"NCT05567185 - CR109248","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 10/16/2026","primary_completion_date":" 10/16/2026","study_txt":" Completion: 09/24/2027","study_completion_date":" 09/24/2027","last_update_posted":"2024-05-22"}]